Abstract 3608
Background
Based on results of the phase 2 BOLT study (NCT01327053), sonidegib 200 mg once daily (QD) was approved in the US for patients with locally advanced basal cell carcinoma (laBCC) not amenable to curative surgery or radiotherapy and in Switzerland and Australia also for metastatic BCC (mBCC). Here we report the final 42-month results—the longest follow-up data available from a hedgehog inhibitor (HHI) clinical trial—for a preplanned prespecified subgroup analysis for the primary endpoint, the objective response rate (ORR), in patients receiving 200 mg.
Methods
BOLT was a double-blind phase 2 study where HHI treatment–naïve patients with laBCC not amenable to curative surgery/radiotherapy, or with metastatic BCC (mBCC) were randomized 1:2 to sonidegib 200 or 800 mg QD, respectively. The primary endpoint was ORR. Analyses were performed at 12, 30, and 42 months after the last patient was randomized.
Results
For prespecified groups at 42 months, the ORRs for 200 mg QD were consistent for laBCC aggressive (59.5%; n = 37) and laBCC nonaggressive (51.7%; n = 29) histologies; male (43.8%; n = 48) and female (54.8%; n = 31); patients aged <65 years (59.4%; n = 32) and those aged ≥65 years (40.4%; n = 47); white (49.3%; n = 71) and nonwhite patients (37.5%; n = 8); and for patients not receiving (51.8%; n = 56) and those receiving (39.1%; n = 23) gastric pH agents. Subgroup analyses by disease strata (laBCC [56.1%; n = 66] vs mBCC [7.7%; n = 13]) and Eastern Cooperative Oncology Group performance status (0 [60%; n = 50] vs ≥ 1 [29.6%; n = 27;]) for the primary ORR endpoint showed heterogeneous results like those reported at 30 months. The safety/tolerability profile was consistent across 42 months with no new AEs emerging.
Conclusions
These results confirmed the consistency of treatment effect for sonidegib 200 mg QD at 42 months across several preplanned subgroups, including age, disease histology, gender, race, and use of gastric pH agents.
Clinical trial identification
NCT01327053.
Legal entity responsible for the study
Sun Pharmaceuticals Ltd.
Funding
Sun Pharmaceuticals Ltd.
Editorial Acknowledgement
Leonard Lionnet, PhD, CMPP of Lev Medical Communications provided medical writing support for this abstract.
Disclosure
R. Dummer: Consultant: Novartis Pharmaceuticals, Sun Pharma.
Resources from the same session
1131 - Role of SPECT-CT somatostatin-receptor scintigraphy in the management of Medullary Thyroid Cancer (MTC)
Presenter: Sonya Sergieva
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5473 - A noninferiority trial of cabozantinib (C) comparing 60 mg vs 140 mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)
Presenter: Jolanta Krajewska
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3367 - The role of SWI/SNF chromatin remodelling complex ATPase subunit – BRM in TNBC
Presenter: Iga Jancewicz
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2026 - Fluoropyrimidine and Inflammatory Genes Promoter Methylation in Egyptian CRC patients
Presenter: Mariam Fouad
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4125 - Realworld prospective data of small biopsy samples for tumor PD-L1 expression in non-small-cell lung cancer
Presenter: Kei Morikawa
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2367 - ATM as a DNA Damage Response Protein in Uveal Melanoma: Association with Clinicopathological Factors and Prognostic Outcome
Presenter: Jayanti Jha
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1305 - BRCA mutation and castration-resistant prostate cancer
Presenter: Liudmila Spirina
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3818 - Prevalence of KRAS mutation subtypes and MSI status in Pancreatic Cancer.
Presenter: Patan Gultawatvichai
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5976 - Molecular signature in malignant pleural mesothelioma (MPM): Preliminary data of Italian RAMES Study
Presenter: Francesca Zanelli
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4763 - N-Myc and STAT interactor (NMI) as a key determinant of chemosensitivity in breast cancer: proteomic-based computing network mapping and in vivo verification with a mouse model
Presenter: Hyebin Lee
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract